Marmoset cytochrome P450 4A11, a novel arachidonic acid and lauric acid ω-hydroxylase expressed in liver and kidney tissues

References

• Adas F, Salaun JP, Berthou F, et al (1999). Requirement for ω and (ω-1)-hydroxylations of fatty acids by human cytochromes P450 2E1 and 4A11. J Lipid Res 40:1990–7
   PubMed Web of Science ®Google Scholar
• Amet Y, Berthou F, Baird S, et al (1995). Validation of the (ω-1)-hydroxylation of lauric acid as an in vitro substrate probe for human liver CYP2E1. Biochem Pharmacol 50:1775–82
   PubMed Web of Science ®Google Scholar
• Arnold C, Markovic M, Blossey K, et al (2010). Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of ω-3 fatty acids. J Biol Chem 285:32720–33
   PubMed Web of Science ®Google Scholar
• Blaauboer BJ, van Holsteijn CW, Bleumink R, et al (1990). The effect of beclobric acid and clofibric acid on peroxisomal beta-oxidation and peroxisome proliferation in primary cultures of rat, monkey and human hepatocytes. Biochem Pharmacol 40:521–8
   PubMed Web of Science ®Google Scholar
• Bouis P, Bieri F, Lang B, et al (1993). Effect of propaquizafop and its free-acid derivative on lauric acid hydroxylation and peroxisomal beta-oxidation in primary cultured rat, mouse, guinea pig and marmoset hepatocytes. Toxicol In Vitro 7:427–31
   PubMed Web of Science ®Google Scholar
• Chang YT, Loew GH. (1999). Homology modeling and substrate binding study of human CYP4A11 enzyme. Proteins 34:403–15
   PubMed Web of Science ®Google Scholar
• Chen L, Ackerman R, Saleh M, et al (2014). 20-HETE regulates the angiogenic functions of human endothelial progenitor cells and contributes to angiogenesis in vivo. J Pharmacol Exp Ther 348:442–51
   PubMed Web of Science ®Google Scholar
• Dierks EA, Zhang Z, Johnson EF, de Montellano PR. (1998). The catalytic site of cytochrome P4504A11 (CYP4A11) and its L131F mutant. J Biol Chem 273:23055–61
   PubMed Web of Science ®Google Scholar
• Edson KZ, Rettie AE. (2013). CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activities. Curr Top Med Chem 13:1429–40
   PubMed Web of Science ®Google Scholar
• El-Sherbeni AA, Aboutabl ME, Zordoky BN, et al (2013). Determination of the dominant arachidonic acid cytochrome p450 monooxygenases in rat heart, lung, kidney, and liver: protein expression and metabolite kinetics. AAPS J 15:112–22
   PubMed Web of Science ®Google Scholar
• Fukuda T, Imai Y, Komori M, et al (1994). Different mechanisms of regioselection of fatty acid hydroxylation by laurate (ω-1)-hydroxylating P450s, P450 2C2 and P450 2E1. J Biochem 115:338–44
   PubMed Web of Science ®Google Scholar
• Hoch U, Ortiz De Montellano PR. (2001). Covalently linked heme in cytochrome p4504a fatty acid hydroxylases. J Biol Chem 276:11339–46
   PubMed Web of Science ®Google Scholar
• Kim D, Cha GS, Nagy LD, et al (2014). Kinetic analysis of lauric acid hydroxylation by human cytochrome P450 4A11. Biochemistry 53:6161–72
   PubMed Web of Science ®Google Scholar
• Kishi N, Sato K, Sasaki E, Okano H. (2014). Common marmoset as a new model animal for neuroscience research and genome editing technology. Dev Growth Differ 56:53–62
   PubMed Web of Science ®Google Scholar
• Lake BG, Evans JG, Gray TJ, et al (1989). Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig, and marmoset. Toxicol Appl Pharmacol 99:148–60
   PubMed Web of Science ®Google Scholar
• Lasker JM, Chen WB, Wolf I, et al (2000). Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J Biol Chem 275:4118–26
   PubMed Web of Science ®Google Scholar
• Lawrence JW, Li Y, Chen S, et al (2001). Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expresson. J Biol Chem 276:31521–7
   PubMed Web of Science ®Google Scholar
• Madan A, DeHaan R, Mudra D, et al (1999). Effect of cryopreservation on cytochrome P-450 enzyme induction in cultured rat hepatocytes. Drug Metab Dispos 27:327–35
   PubMed Web of Science ®Google Scholar
• Makowska JM, Bonner FW, Gibson GG. (1991). Comparative induction of cytochrome P450IVA1 and peroxisome proliferation by ciprofibrate in the rat and marmoset. Arch Toxicol 65:106–13
   PubMed Web of Science ®Google Scholar
• Mayumi K, Hanioka N, Masuda K, et al (2013). Characterization of marmoset CYP2B6: cDNA cloning, protein expression and enzymatic functions. Biochem Pharmacol 85:1182–94
   PubMed Web of Science ®Google Scholar
• Mitchell SR, Sewer MB, Kardar SS, Morgan ET. (2001). Characterization of CYP4A induction in rat liver by inflammatory stimuli: dependence on sex, strain, and inflammation-evoked hypophagia. Drug Metab Dispos 29:17–22
   PubMed Web of Science ®Google Scholar
• Nishimura M, Yaguti H, Yoshitsugu H, et al (2003). Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123:369–75
   PubMed Web of Science ®Google Scholar
• Powell PK, Wolf I, Jin R, Lasker JM. (1998). Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11. J Pharmacol Exp Ther 285:1327–36
   PubMed Web of Science ®Google Scholar
• Raucy JL, Lasker J, Ozaki K, Zoleta V. (2004). Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. Toxicol Sci 79:233–41
   PubMed Web of Science ®Google Scholar
• Richert L, Lamboley C, Viollon-Abadie C, et al (2003). Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytes. Toxicol Appl Pharmacol 191:130–46
   PubMed Web of Science ®Google Scholar
• Schulz TG, Thiel R, Davies DS, Edwards RJ. (1998). Identification of CYP2E1 in marmoset monkey. Biochim Biophys Acta 1382:287–94
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–23
   PubMed Web of Science ®Google Scholar
• Shimizu M, Iwano S, Uno Y, et al (2014). Qualitative de novo analysis of full length cDNA and quantitative analysis of gene expression for common marmoset (Callithrix jacchus) transcriptomes using parallel long-read technology and short-read sequencing. PLoS One 9:e100936
   PubMed Web of Science ®Google Scholar
• Uehara S, Inoue T, Utoh M, et al (2016a). Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). Xenobiotica 46:163–8
   PubMed Web of Science ®Google Scholar
• Uehara S, Uno Y, Hagihira Y, et al (2015a). Marmoset cytochrome P450 2D8 in livers and small intestines metabolizes typical human P450 2D6 substrates, metoprolol, bufuralol and dextromethorphan. Xenobiotica 45:766–72
   PubMed Web of Science ®Google Scholar
• Uehara S, Uno Y, Inoue T, et al (2015b). Novel marmoset cytochrome P450 2C19 in livers efficiently metabolizes human P450 2C9 and 2C19 substrates, S-Warfarin, Tolbutamide, Flurbiprofen, and Omeprazole. Drug Metab Dispos 43:1408–16
   PubMed Web of Science ®Google Scholar
• Uehara S, Uno Y, Inoue T, et al (2015c). Substrate selectivities and catalytic activities of marmoset liver cytochrome P450 2A6 differed from those of human P450 2A6. Drug Metab Dispos 43:969–76
   PubMed Web of Science ®Google Scholar
• Uehara S, Uno Y, Inoue T, et al (2016b). Marmoset cytochrome P450 2J2 mainly expressed in small intestines and livers effectively metabolizes human P450 2J2 probe substrates, astemizole and terfenadine. Xenobiotica. [Epub ahead of print]. doi: 10.3109/00498254.2016.1146366
   Web of Science ®Google Scholar
• Uehara S, Uno Y, Inoue T, et al (2016c). Molecular cloning, tissue distribution, and functional characterization of marmoset cytochrome P450 1A1, 1A2, and 1B1. Drug Metab Dispos 44:8–15
   PubMed Web of Science ®Google Scholar
• Uehara S, Uno Y, Yuki Y, et al (2016d). A new marmoset P450 4F12 enzyme expressed in small intestines and livers efficiently metabolizes antihistaminic drug ebastine. Drug Metab Dispos 44:833–41
   PubMed Web of Science ®Google Scholar
• Uno Y, Hosaka S, Matsuno K, et al (2007). Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism? Arch Biochem Biophys 466:98–105
   PubMed Web of Science ®Google Scholar
• Uno Y, Matsuno K, Nakamura C, et al (2011). Cynomolgus macaque CYP4 isoforms are functional, metabolizing arachidonic acid. J Vet Med Sci 73:487–90
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Nakamura M, Komatsu T, et al (2002). Roles of NADPH-P450 reductase and apo-and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr Purif 24:329–37
   PubMed Web of Science ®Google Scholar
• Yasui H, Deo K, Ogura Y, et al (2002). Evidence for singlet oxygen involvement in rat and human cytochrome P450-dependent substrate oxidations. Drug Metab Pharmacokinet 17:416–26
   PubMedGoogle Scholar